Company research
Loading SEC business and financials…
AI relationship research has not yet been verified for this company.
Listing data synced 2026-04-16.
Loading your outlook…
Loading…
Loading company activity...
Estimated market cap
Unavailable
A supported share count and cached closing price are required.
Annual report for the year ended 2025-12-31. These are reported annual figures, not trailing twelve-month estimates.
Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (“LN”). Aurinia is also developing aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for the potential treatment of autoimmune diseases.
Excerpt from Item 1 — Business; filed 2026-02-26. May be shortened.
Source: SEC Company Facts. Checked 2026-09-25. Data is refreshed in the background. Missing or ambiguous figures are left unavailable.
Showing a previously fetched snapshot. A recent refresh has not completed.
